Comparative Pharmacology
Head-to-head clinical analysis: CYSVIEW KIT versus EVANS BLUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSVIEW KIT versus EVANS BLUE.
CYSVIEW KIT vs EVANS BLUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholic acid is a primary bile acid that acts as a choleretic and bile acid replacement therapy. It competitively inhibits hepatic bile acid synthesis via negative feedback on cholesterol 7α-hydroxylase (CYP7A1), reducing the production of toxic bile acid intermediates in patients with inborn errors of bile acid synthesis.
Evans Blue is a diazo dye that binds reversibly to plasma proteins, primarily albumin. Its primary utility is as a visual indicator for the estimation of blood volume or plasma volume via dye dilution technique. It also has histological applications for staining myelin sheaths and detecting blood-brain barrier disruption.
Intravenous: 5 mg/kg as a single dose administered over 30 minutes.
Adults: 0.5-1.0 mL of 0.5% solution (2.5-5 mg) IV bolus for determination of blood volume. Repeat doses must be separated by at least 1 hour due to slow clearance.
None Documented
None Documented
Terminal elimination half-life: 1.9-2.5 hours (mean 2.1 h) in normal renal function; prolonged in renal impairment (up to 20 h in ESRD).
Terminal elimination half-life ranges from 2 to 12 hours, mean approximately 6 hours; prolonged in hepatic impairment or decreased albumin levels.
Renal: 90% unchanged via glomerular filtration; biliary/fecal: <5%
Primarily excreted unchanged in bile (80-90%) into feces; renal elimination accounts for <5% due to high protein binding.
Category C
Category C
Diagnostic Dye
Diagnostic Dye